Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT05921903
Registration number
NCT05921903
Ethics application status
Date submitted
16/06/2023
Date registered
27/06/2023
Date last updated
16/07/2025
Titles & IDs
Public title
A Study on the Immune Response and Safety of an RSV Vaccine When Given to Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant and Are at an Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease and Compared to Healthy Adults 50 Years of Age and Above
Query!
Scientific title
A Phase 2b, Randomized, Controlled, Open-label Study to Evaluate the Immune Response and Safety of the RSVPreF3 OA Investigational Vaccine in Adults (>=18 Years of Age) When Administered to Lung and Renal Transplant Recipients Comparing 1 Versus 2 Doses and Compared to Healthy Controls (>=50 Years of Age) Receiving 1 Dose.
Query!
Secondary ID [1]
0
0
2023-503951-81-00
Query!
Secondary ID [2]
0
0
219900
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
RSV OA=ADJ-023
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Respiratory Syncytial Virus Infections
0
0
Query!
Condition category
Condition code
Respiratory
0
0
0
0
Query!
Other respiratory disorders / diseases
Query!
Infection
0
0
0
0
Query!
Other infectious diseases
Query!
Infection
0
0
0
0
Query!
Studies of infection and infectious agents
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Other - RSVPreF3 OA Investigational Vaccine
Experimental: RSV_IC_1 group - Immunocompromised (IC) participants (recipients of lung or renal transplant) received 1 dose of RSVPreF3 OA investigational vaccine at Visit 1 (Day 1).
Experimental: RSV_IC_2 group - IC participants (recipients of lung or renal transplant) received 2 doses of RSVPreF3 OA investigational vaccine at Visit 1 (Day 1) and Visit 3 (Visit 1 + 30-60 days).
Active comparator: RSV_HA group - Healthy adult (HA) participants received 1 dose of RSVPreF3 OA investigational vaccine at Visit 1 (Day 1).
Treatment: Other: RSVPreF3 OA Investigational Vaccine
0.5 mililiter dose was administered intramuscularly as 1 dose to RSV_IC_1 and RSV_HA groups, and 2 doses to RSV_IC_2 group.
Query!
Intervention code [1]
0
0
Treatment: Other
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
RSV-A Serum Neutralizing Titers Expressed As Mean Geometric Increase (MGI) Post-Dose 2 (Visit 4) Over Post-Dose 1 (Visit 3) for RSV_IC_2 Group
Query!
Assessment method [1]
0
0
MGI was defined as the geometric mean of the within-participant ratios of serum neutralizing titers against RSV-A post-Dose 2 (Visit 4) over post-Dose 1 (Visit 3).
Query!
Timepoint [1]
0
0
At Visit 4 (Visit 3 + 30-42 days) compared with Visit 3 (Visit 1 [Day 1] + 30-60 days)
Query!
Primary outcome [2]
0
0
RSV-B Serum Neutralizing Titers Expressed As MGI Post-Dose 2 (Visit 4) Over Post-Dose 1 (Visit 3) for RSV_IC_2 Group
Query!
Assessment method [2]
0
0
MGI was defined as the geometric mean of the within-participant ratios of serum neutralizing titers against RSV-B post-Dose 2 (Visit 4) over post-Dose 1 (Visit 3).
Query!
Timepoint [2]
0
0
At Visit 4 (Visit 3 + 30-42 days) compared with Visit 3 (Visit 1 [Day 1] + 30-60 days)
Query!
Secondary outcome [1]
0
0
RSV-A And RSV-B Serum Neutralizing Titers Expressed As Geometric Mean Titers (GMT) for RSV_IC_1, RSV_IC_2 and RSV_HA Groups
Query!
Assessment method [1]
0
0
Neutralizing titers were calculated as GMT and expressed in titers (Estimated Dilution 60 \[ED60\]).
Query!
Timepoint [1]
0
0
At pre-study intervention administration (at Visit 1 [Day 1]), Visit 2 in a subset of participants (Visit 1 + 7-14 days), Visit 3 (Visit 1 + 30-60 days) and Visit 4 (Visit 3 + 30-42 days)
Query!
Secondary outcome [2]
0
0
RSV-A and RSV-B Serum Neutralizing Titers Expressed as GMT for RSV_IC_1, RSV_IC_2 and RSV_HA Groups
Query!
Assessment method [2]
0
0
Neutralizing titers were calculated as GMT and expressed in titers (ED60).
Query!
Timepoint [2]
0
0
At Visit 5 (last dose + 180-210 days) and Visit 6 (last dose + 350-380 days)
Query!
Secondary outcome [3]
0
0
RSV-A Serum Neutralizing Titers Expressed As Group GMT For RSV_HA And Pooled RSV_IC Groups
Query!
Assessment method [3]
0
0
Group GMT was assessed for RSV_HA group over pooled RSV_IC group (combined RSV_IC_1 and RSV_IC_2 groups). The ANCOVA model used to calculate the adjusted GMTs for RSV-A neutralizing titers included the baseline log10-transformed titer as covariate (i.e. GMTs are adjusted for the PRE timepoint values) and only included RSV_HA and Pooled RSV_IC groups in the model as fixed effect, as specified in Statistical Analysis Plan.
Query!
Timepoint [3]
0
0
At Visit 2 in a subset of participants (Visit 1 [Day 1] + 7-14 days) and Visit 3 (Visit 1 + 30-60 days)
Query!
Secondary outcome [4]
0
0
RSV-A Serum Neutralizing Titers Expressed As Group GMT For RSV_IC_1 And RSV_IC_2 Groups
Query!
Assessment method [4]
0
0
Group GMT of RSV_IC_2 over RSV_IC_1 was assessed at Visit 4. The ANCOVA model used to calculate the adjusted GMTs for RSV-A neutralizing titers included the baseline log10-transformed titer and the SOT type as covariate (i.e. GMTs are adjusted for the PRE timepoint values) and only included RSV_IC_1 and RSV_IC_2 groups in the model as fixed effect, as specified in Statistical Analysis Plan.
Query!
Timepoint [4]
0
0
At Visit 4 (Visit 3 [Visit 1 (Day 1) + 30-60 days] + 30-42 days)
Query!
Secondary outcome [5]
0
0
RSV-A Serum Neutralizing Titers Expressed As Group GMT For RSV_IC_1 And RSV_HA Groups
Query!
Assessment method [5]
0
0
Group GMT of RSV_HA over RSV_IC_1 was assessed at Visit 4. The ANCOVA model used to calculate the adjusted GMTs for RSV-A neutralizing titers included the baseline log10-transformed titer as covariate (i.e. GMTs are adjusted for the PRE timepoint values) and only included RSV_IC_1 and RSV_HA groups in the model as fixed effect, as specified in Statistical Analysis Plan.
Query!
Timepoint [5]
0
0
At Visit 4 (Visit 3 [Visit 1 (Day 1) + 30-60 days] + 30-42 days)
Query!
Secondary outcome [6]
0
0
RSV-A Serum Neutralizing Titers Expressed As Group GMT For RSV_IC_2 And RSV_HA Groups
Query!
Assessment method [6]
0
0
Group GMT of RSV_HA over RSV_IC_2 was assessed at Visit 4. The ANCOVA model used to calculate the adjusted GMTs for RSV-A neutralizing titers included the baseline log10-transformed titer as covariate (i.e. GMTs are adjusted for the PRE timepoint values) and only included RSV_IC_2 and RSV_HA groups in the model as fixed effect, as specified in Statistical Analysis Plan.
Query!
Timepoint [6]
0
0
At Visit 4 (Visit 3 [Visit 1 (Day 1) + 30-60 days] + 30-42 days)
Query!
Secondary outcome [7]
0
0
RSV-A Serum Neutralizing Titers Expressed as Group GMT for RSV_IC_1, RSV_IC_2 and RSV_HA Groups
Query!
Assessment method [7]
0
0
Query!
Timepoint [7]
0
0
At Visit 5 (last dose + 180-210 days) and Visit 6 (last dose + 350-380 days)
Query!
Secondary outcome [8]
0
0
RSV-B Serum Neutralizing Titers Expressed As Group GMT For RSV_HA And Pooled RSV_IC Groups
Query!
Assessment method [8]
0
0
Group GMT was assessed for RSV_HA group over pooled RSV_IC group (combined RSV_IC_1 and RSV_IC_2 groups). The ANCOVA model used to calculate the adjusted GMTs for RSV-B neutralizing titers included the baseline log10-transformed titer as covariate (i.e. GMTs are adjusted for the PRE timepoint values) and only included RSV_HA and Pooled RSV_IC groups in the model as fixed effect, as specified in Statistical Analysis Plan.
Query!
Timepoint [8]
0
0
At Visit 2 in a subset of participants (Visit 1 [Day 1] + 7-14 days) and Visit 3 (Visit 1 + 30-60 days)
Query!
Secondary outcome [9]
0
0
RSV-B Serum Neutralizing Titers Expressed As Group GMT For RSV_IC_1 And RSV_IC_2 Groups
Query!
Assessment method [9]
0
0
Group GMT ratio of RSV_IC_2 over RSV_IC_1 was assessed at Visit 4. The ANCOVA model used to calculate the adjusted GMTs for RSV-B neutralizing titers included the baseline log10-transformed titer and the SOT type as covariate (i.e. GMTs are adjusted for the PRE timepoint values) and only included RSV_IC_1 and RSV_IC_2 groups in the model as fixed effect, as specified in Statistical Analysis Plan.
Query!
Timepoint [9]
0
0
At Visit 4 (Visit 3 [Visit 1 (Day 1) + 30-60 days] + 30-42 days)
Query!
Secondary outcome [10]
0
0
RSV-B Serum Neutralizing Titers Expressed As Group GMT For RSV_IC_1 And RSV_HA Groups
Query!
Assessment method [10]
0
0
Group GMT of RSV_HA over RSV_IC_1 was assessed at Visit 4. The ANCOVA model used to calculate the adjusted GMTs for RSV-B neutralizing titers included the baseline log10-transformed titer as covariate (i.e. GMTs are adjusted for the PRE timepoint values) and only included RSV_IC_1 and RSV_HA groups in the model as fixed effect, as specified in Statistical Analysis Plan.
Query!
Timepoint [10]
0
0
At Visit 4 (Visit 3 [Visit 1 (Day 1) + 30-60 days] + 30-42 days)
Query!
Secondary outcome [11]
0
0
RSV-B Serum Neutralizing Titers Expressed As Group GMT For RSV_IC_2 And RSV_HA Groups
Query!
Assessment method [11]
0
0
Group GMT of RSV_HA over RSV_IC_2 was assessed at Visit 4. The ANCOVA model used to calculate the adjusted GMTs for RSV-B neutralizing titers included the baseline log10-transformed titer as covariate (i.e. GMTs are adjusted for the PRE timepoint values) and only included RSV_IC_2 and RSV_HA groups in the model as fixed effect, as specified in Statistical Analysis Plan.
Query!
Timepoint [11]
0
0
At Visit 4 (Visit 3 [Visit 1 (Day 1) + 30-60 days] + 30-42 days)
Query!
Secondary outcome [12]
0
0
RSV-B Serum Neutralizing Titers Expressed as Group GMT for RSV_IC_1, RSV_IC_2 and RSV_HA Groups
Query!
Assessment method [12]
0
0
Query!
Timepoint [12]
0
0
At Visit 5 (last dose +180-210 days) and Visit 6 (last dose + 350-380 days)
Query!
Secondary outcome [13]
0
0
RSV-A And RSV-B Serum Neutralizing Titers Expressed As MGI
Query!
Assessment method [13]
0
0
MGI was assessed at Visit 2 (in a subset of participants) over Visit 1 and Visit 3 over Visit 1 in RSV_HA and pooled RSV_IC (combined RSV_IC_1 and RSV_IC_2 groups), and at Visit 4 over Visit 1 in RSV_IC_1, RSV_IC_2, RSV_HA groups.
Query!
Timepoint [13]
0
0
At Visit 2 in a subset of participants (Visit 1 [Day 1] + 7-14 days), Visit 3 (Visit 1 + 30-60 days) and Visit 4 (Visit 3 + 30-42 days), each compared to Visit 1 (Day 1)
Query!
Secondary outcome [14]
0
0
RSV-A and RSV-B Serum Neutralizing Titers Expressed as MGI
Query!
Assessment method [14]
0
0
Query!
Timepoint [14]
0
0
At Visit 5 (last dose +180-210 days) and Visit 6 (last dose + 350-380 days), each compared with Visit 1 (Day 1)
Query!
Secondary outcome [15]
0
0
Cell Mediated Immunity (CMI) Response In A Subset of Participants Expressed As Group Geometric Mean Of The Frequency Of RSVPreF3-Specific Cluster Of Differentiation (CD) 4+ T Cells
Query!
Assessment method [15]
0
0
CMI response is expressed as group geometric mean of the frequency of RSVPreF3-specific cluster of differentiation CD4+ T cells expressing at least 2 activation markers including at least one cytokine among CD40L, 4-1BB, IL-2, TNF-alpha, IFN-gamma, IL- 13 and IL-17. The CMI is measured in a subgroup consisting of participants with renal and lung SOT (from RSV_IC_1 and RSV_IC_2 groups) and healthy participants (from RSV_HA group).
Query!
Timepoint [15]
0
0
At pre-study intervention administration (at Visit 1 [Day 1]), Visit 2 (Visit 1 + 7-14 days), Visit 3 (Visit 1 + 30-60 days) and Visit 4 (Visit 3 + 30-42 days)
Query!
Secondary outcome [16]
0
0
CMI Response In A Subset of Participants Expressed As Group Geometric Mean Of The Frequency Of RSVPreF3-Specific CD8+ T Cells
Query!
Assessment method [16]
0
0
CMI response is expressed as group geometric mean of the frequency of RSVPreF3-specific CD8+ T cells expressing at least 2 activation markers including at least one cytokine among CD40L, 4-1BB, IL-2, TNF-alpha, IFN-gamma, IL- 13 and IL-17. The CMI is measured in a subgroup consisting of participants with renal and lung SOT (from RSV_IC_1 and RSV_IC_2 groups) and healthy participants (from RSV_HA group).
Query!
Timepoint [16]
0
0
At pre-study intervention administration (at Visit 1 [Day 1]), Visit 2 (Visit 1 + 7-14 days), Visit 3 (Visit 1 + 30-60 days) and Visit 4 (Visit 3 + 30-42 days)
Query!
Secondary outcome [17]
0
0
CMI Response in a Subset of Participants
Query!
Assessment method [17]
0
0
Query!
Timepoint [17]
0
0
At Visit 5 (last dose + 180-210 days) and Visit 6 (last dose + 350-380 days)
Query!
Secondary outcome [18]
0
0
Number Of Participants Reporting Any Solicited Administration Site Events
Query!
Assessment method [18]
0
0
Assessed solicited administration site events included pain, erythema (redness) and swelling, at the injection site. Any = occurrence of the symptom regardless of intensity grade or relation to study intervention.
Query!
Timepoint [18]
0
0
Within 7 days (i.e., the day of vaccination and 6 subsequent days) after vaccine administration (vaccine administered at Visit 1 [Day 1] for all groups, and Visit 3 [Visit 1 +30-60 days] for RSV_IC_2 group)
Query!
Secondary outcome [19]
0
0
Number Of Participants Reporting Any Solicited Systemic Events
Query!
Assessment method [19]
0
0
Assessed solicited systemic events included fever (pyrexia), myalgia, arthralgia, headache, and fatigue. Fever is defined as body temperature greater or equal to (=) 38 degrees Celsius (ºC). Any = occurrence of the symptom regardless of intensity grade or relation to study intervention.
Query!
Timepoint [19]
0
0
Within 7 days (i.e., the day of vaccination and 6 subsequent days) after vaccine administration (vaccine administered at Visit 1 [Day 1] for all groups, and Visit 3 [Visit 1 +30-60 days] for RSV_IC_2 group)
Query!
Secondary outcome [20]
0
0
Number Of Participants Reporting Any Unsolicited Adverse Events (AEs) At Any Dose Administration
Query!
Assessment method [20]
0
0
An unsolicited AE is an AE that was not included in the list of solicited events. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms is to be reported as an unsolicited AE. Any = occurrence of the symptom regardless of intensity grade or relation to study intervention.
Query!
Timepoint [20]
0
0
Within 30 days (i.e., the day of vaccination and 29 subsequent days) after vaccine administration (vaccine administered at Visit 1 [Day 1] for all groups, and Visit 3 [Visit 1 +30-60 days] for RSV_IC_2 group)
Query!
Secondary outcome [21]
0
0
Number Of Participants Reporting Any Serious Adverse Events (SAEs), SAEs Related To Study Intervention And Fatal SAEs
Query!
Assessment method [21]
0
0
A SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity or is a congenital anomaly/birth defect in the offspring of a study participant. Any SAE = occurrence of the SAE regardless of relation to study vaccination. Related SAE = SAE assessed by the investigator as related to the study vaccination. Fatal SAE = occurrence of a fatal SAE regardless of relation to study vaccination.
Query!
Timepoint [21]
0
0
From Visit 1 (Day 1) up to Visit 4 (Visit 3 + 30-42 days) after vaccine administration (vaccine administered at Visit 1 [Day 1] for all groups, and Visit 3 [Visit 1 + 30-60 days] for RSV_IC_2 group)
Query!
Secondary outcome [22]
0
0
Number Of Participants Reporting Any Potential Immune-Mediated Disease (pIMDs) And pIMDs Related To Study Intervention
Query!
Assessment method [22]
0
0
pIMDs are a subset of AESIs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology. Any pIMDs = occurrence of the pIMDs regardless of relation to study vaccination. Related pIMDs = pIMDs assessed by the investigator as related to the study vaccination.
Query!
Timepoint [22]
0
0
From Visit 1 (Day 1) up to Visit 4 (Visit 3 + 30-42 days) after vaccine administration (vaccine administered at Visit 1 [Day 1] for all groups, and Visit 3 [Visit 1 + 30-60 days] for RSV_IC_2 group)
Query!
Secondary outcome [23]
0
0
Number Of Participants With Any AEs Of Special Interest (AESIs) Specific To Renal And Lung SOT Participants
Query!
Assessment method [23]
0
0
AESIs include the acute rejection of transplant (specific to renal and lung SOT participants). Analysis was performed only on participants that received transplant in RSV_IC_1 and RSV_IC_2 groups.
Query!
Timepoint [23]
0
0
From Visit 1 (Day 1) up to Visit 4 (Visit 3 + 30-42 days) after vaccine administration (vaccine administered at Visit 1 [Day 1] for all groups, and Visit 3 [Visit 1 + 30-60 days] for RSV_IC_2 group)
Query!
Secondary outcome [24]
0
0
Number of Participants Reporting Any SAEs, SAEs Related to Study Intervention and Fatal SAEs
Query!
Assessment method [24]
0
0
A SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity or is a congenital anomaly/birth defect in the offspring of a study participant. Any SAE = occurrence of the SAE regardless of relation to study vaccination. Related SAE = SAE assessed by the investigator as related to the study vaccination. Fatal SAE = occurrence of a fatal SAE regardless of relation to study vaccination.
Query!
Timepoint [24]
0
0
From Visit 1 (Day 1) up to study end (Visit 6 - last dose + 350-380 days), vaccine administered at Visit 1 [Day 1] for all groups, and Visit 3 [Visit 1 + 30-60 days] for RSV_IC_2 group)
Query!
Secondary outcome [25]
0
0
Number of Participants Reporting Any pIMDs and pIMDs Related to Study Intervention
Query!
Assessment method [25]
0
0
pIMDs are a subset of AESIs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology. Any pIMDs = occurrence of the pIMDs regardless of relation to study vaccination. Related pIMDs = pIMDs assessed by the investigator as related to the study vaccination.
Query!
Timepoint [25]
0
0
From Visit 1 (Day 1) up to study end (Visit 6 - last dose + 350-380 days), vaccine administered at Visit 1 [Day 1] for all groups, and Visit 3 [Visit 1 + 30-60 days] for RSV_IC_2 group)
Query!
Secondary outcome [26]
0
0
Number of Participants Reporting Any AESIs Specific to Renal and Lung SOT Participants
Query!
Assessment method [26]
0
0
AESIs include the acute rejection of transplant (specific to renal and lung SOT participants). Analysis was performed only on participants that received transplant in RSV_IC_1 and RSV_IC_2 groups.
Query!
Timepoint [26]
0
0
From Visit 1 (Day 1) up to study end (Visit 6 - last dose + 350-380 days), vaccine administered at Visit 1 [Day 1] for all groups, and Visit 3 [Visit 1 + 30-60 days] for RSV_IC_2 group)
Query!
Eligibility
Key inclusion criteria
* Participants and/or participant's parent(s)/LAR(s) who, in the opinion of the investigator, can and will comply with the requirements of the protocol.
* Participants living in the general community or in an assisted-living facility that provides minimal assistance can be enrolled, such that the participant is primarily responsible for self-care and activities of daily living.
* Written or witnessed informed consent obtained from the participant/participant's parent(s)/LAR(s) (participant must be able to understand the informed consent) prior to performance of any study-specific procedure.
* Female participants of nonchildbearing potential may be enrolled in the study. Non-childbearing potential is defined as hysterectomy, bilateral oophorectomy, bilateral salpingectomy, and post-menopause.
* Female participants of childbearing potential may be enrolled in the study if the participant has practiced adequate contraception from 1 month prior to study intervention administration and agreed to continue adequate contraception until study end for this study, and has a negative pregnancy test on the day of and prior to study intervention administration.
Specific inclusion criteria for renal/lung transplant patients:
* A male or female, >=18 YoA at the time of signing the Informed consent form (ICF) or Informed assent form (IAF).
* Written informed assent obtained from the participant (participant must be able to understand the informed assent) if he/she is less than legal age of consent, or written informed consent obtained from the participant if the participant has achieved legal age of consent.
* Participant who has received an ABO compatible allogeneic renal or lung transplant (allograft) more than 12 months (365 days) prior to the first study intervention administration.
* Participant receiving maintenance immunosuppressive therapy for the prevention of allograft rejection.
Specific inclusion criteria for renal transplant (RTx) patients:
• Participant with stable renal function, stability defined as less than 20% variability between last two results of eGFR or in the opinion of the investigator after investigator review of more than the last two results of eGFRs and based on medical history.
Specific inclusion criteria for lung transplant (LTx) patients:
• Participant with stable lung function, with stability defined as the stability in the FEV1 compared to post-transplant baseline FEV1 and based on medical history of the last 3 months, in the opinion of the investigator.
Specific inclusion criteria for healthy participants:
* A male or female, >=50 YoA at the time of signing the ICF.
* Healthy participants as established by medical history and clinical examination before entering the study.
* Participants who are medically stable in the opinion of the investigator at the time of first study intervention administration.
* Participants with chronic stable medical conditions with or without specific treatment, such as diabetes mellitus, hypertension, or cardiac disease, are allowed to participate in this study if considered by the investigator as medically stable.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
Yes
Query!
Key exclusion criteria
Medical conditions:
* History of any reaction/ hypersensitivity likely to be exacerbated by any component of the study intervention.
* Acute or chronic clinically significant cardiovascular or hepatic functional abnormality as determined by physical examination or laboratory screening tests.
* Recurrent/uncontrolled neurological disorders or seizures. Participants with medically controlled chronic neurological diseases can be enrolled in the study if their condition will allow them to comply with the requirements of the protocol, with the help of a caregiver if needed.
* Any history of dementia or any medical condition that moderately or severely impairs cognition.
* Any condition which would make IM injection unsafe.
* Significant underlying illness that would prevent completion of the study).
* Acute disease and/or fever at the time of study intervention administration (>=38°C /100.4°F, oral or axillary). Participants with a minor illness without fever may be enrolled at the discretion of the investigator.
* Bedridden participants.
Prior/Concomitant therapy:
* Use of any other investigational or non-registered product (drug, vaccine, or medical device) up to 30 days before the first dose administration (Day -30 to Day 1), or their planned use during the study period (up to Visit 6).
* Previous vaccination with the study antigen (RSV), including investigational RSV vaccines.
* Unexpected vaccine administration during a study should not occur 30 days prior to the first dose or 30 days after the last dose. For COVID-19 and inactivated/subunit/split influenza vaccines, this window is shortened to 14 days.
Prior/Concurrent clinical study experience:
• Concurrently participating in another active clinical study
Other exclusion criteria:
* Pregnant or lactating female participant.
* Female participant planning to become pregnant or planning to discontinue contraceptive precautions.
* History of chronic alcohol consumption and/or drug abuse
* Participation of any study personnel or their immediate dependents.
* Planned move during the study period that will prohibit participating in the study until study end.
Specific exclusion criteria for renal/lung transplant patients:
* More than one organ transplanted. Dual organ is allowed.
* History of events that may put the participant at increased risk for chronic allograft dysfunction.
* Participant with an episode of allograft rejection over the previous 90 days prior to the first study intervention administration.
* Histologic evidence of chronic allograft injury.
* Active treatment for acute rejection.
* Current diagnosis of malignancy (except non-melanoma skin cancer that does not require systemic therapy).
* Any autoimmune conditions or pIMDs that may put the participant at increased risk.
* Any confirmed or suspected HIV infection, primary immunodeficiency disease or ongoing CMV infection with a viremia >200 IU/mL.
* Use of anti-CD20 or other B-cell monoclonal antibody agents for the prevention of allograft rejection within 274 days of first dose of study.
* Use of investigational and non-registered immunosuppressants at the local/country level, unless specifically prescribed for the prevention of allograft rejection, and which are in process of approval, approved in other countries and locally available.
* Evidence/high suspicion of noncompliance/nonadherence to use of induction and/or maintenance immunosuppressive therapies.
* Any clinically significant hematologic and/or biochemical laboratory abnormality.
Specific exclusion criteria for RTx patients:
* Previous allograft loss secondary to recurrent primary kidney disease. Multiple consecutive kidney transplants are allowed if the reason is not recurrent primary kidney disease.
* Evidence of significant proteinuria/albuminuria.
Specific exclusion criteria for LTx patients:
* At study intervention administration visit, diagnosis of documented acute pulmonary infection within the 2 prior weeks.
* Patients with diagnosis of chronic lung allograft dysfunction (decrement of >=20% in FEV1 compared to post-transplant baseline FEV1).
Specific exclusion criteria for healthy participants:
* Any confirmed/suspected immunosuppressive/immunodeficient condition resulting from disease or immunosuppressive/cytotoxic therapy, based on medical history and physical examination.
* Unstable serious chronic illness.
* Chronic administration of immune-modifying drugs (>14 days in total) and/or administration of long-acting immune-modifying treatments or planned administration at any time up to the end of the study.
* Up to 3 months prior to the study intervention administration:
* For corticosteroids -prednisone equivalent =20 mg/day, or equivalent. Inhaled, topical and intra-articular steroids are allowed.
* Administration of immunoglobulins and/or any blood products or plasma derivatives.
* Up to 6 months prior to study intervention administration: long-acting immune-modifying drugs.
Query!
Study design
Purpose of the study
Prevention
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
28/07/2023
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
16/05/2025
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
386
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA
Query!
Recruitment hospital [1]
0
0
GSK Investigational Site - Camperdown
Query!
Recruitment hospital [2]
0
0
GSK Investigational Site - Birtinya
Query!
Recruitment hospital [3]
0
0
GSK Investigational Site - Herston
Query!
Recruitment hospital [4]
0
0
GSK Investigational Site - Adelaide
Query!
Recruitment postcode(s) [1]
0
0
2050 - Camperdown
Query!
Recruitment postcode(s) [2]
0
0
4556 - Birtinya
Query!
Recruitment postcode(s) [3]
0
0
4029 - Herston
Query!
Recruitment postcode(s) [4]
0
0
5000 - Adelaide
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arizona
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Illinois
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Kentucky
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Minnesota
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Missouri
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Nebraska
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
New York
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Pennsylvania
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Texas
Query!
Country [10]
0
0
Canada
Query!
State/province [10]
0
0
Alberta
Query!
Country [11]
0
0
Canada
Query!
State/province [11]
0
0
British Columbia
Query!
Country [12]
0
0
Canada
Query!
State/province [12]
0
0
Ontario
Query!
Country [13]
0
0
Canada
Query!
State/province [13]
0
0
Quebec
Query!
Country [14]
0
0
Germany
Query!
State/province [14]
0
0
Giessen
Query!
Country [15]
0
0
Italy
Query!
State/province [15]
0
0
Milano
Query!
Country [16]
0
0
Italy
Query!
State/province [16]
0
0
Palermo
Query!
Country [17]
0
0
Italy
Query!
State/province [17]
0
0
Pavia
Query!
Country [18]
0
0
Italy
Query!
State/province [18]
0
0
Siena
Query!
Country [19]
0
0
Japan
Query!
State/province [19]
0
0
Aichi
Query!
Country [20]
0
0
Japan
Query!
State/province [20]
0
0
Fukuoka
Query!
Country [21]
0
0
Japan
Query!
State/province [21]
0
0
Hyogo
Query!
Country [22]
0
0
Japan
Query!
State/province [22]
0
0
Kumamoto
Query!
Country [23]
0
0
Japan
Query!
State/province [23]
0
0
Okayama
Query!
Country [24]
0
0
Japan
Query!
State/province [24]
0
0
Tokyo
Query!
Country [25]
0
0
Korea, Republic of
Query!
State/province [25]
0
0
Seoul
Query!
Country [26]
0
0
Spain
Query!
State/province [26]
0
0
A Coruna
Query!
Country [27]
0
0
Spain
Query!
State/province [27]
0
0
Barcelona
Query!
Country [28]
0
0
Spain
Query!
State/province [28]
0
0
Cordoba
Query!
Country [29]
0
0
Spain
Query!
State/province [29]
0
0
Madrid
Query!
Country [30]
0
0
Spain
Query!
State/province [30]
0
0
Santander
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
GlaxoSmithKline
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is to evaluate the immunogenicity, safety, and reactogenicity of the RSVPreF3 OA investigational vaccine in an immunocompromised (lung and renal transplant recipients) population and assess whether a second dose of the vaccine increases the immune response.
Query!
Trial website
https://clinicaltrials.gov/study/NCT05921903
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Data sharing statement
What supporting documents are/will be available?
No Supporting Document Provided
Type
Other Details
Attachment
Study protocol
https://cdn.clinicaltrials.gov/large-docs/03/NCT05921903/Prot_000.pdf
Statistical analysis plan
https://cdn.clinicaltrials.gov/large-docs/03/NCT05921903/SAP_001.pdf
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results are available at
https://clinicaltrials.gov/study/NCT05921903
Download to PDF